News

Changing the Face of Clinical Trials

Leslie Harris O'Hanlon
"Overall, only about 5 to 10 percent of cancer patients participate in clinical trials. And when it comes to African-American cancer patients, the figures are even lower: 2 to 4 percent. This low participation makes it difficult for researchers to get answers to critical questions: Why are African-Americans more likely to develop certain cancers than other racial and ethnic groups and have higher death rates for some types of the disease? Is it lifestyle? Genetics? Treatment response? Access to health care? No one yet knows. But researchers believe that increasing the number of African-Americans in cancer trials will help them find out. So that can happen, more efforts are under way to identify the reasons that so few African-American cancer patients join clinical trials and to implement programs that can put them on the clinical trials track.


Questions and Concerns
"Increasing African-American participation in clinical trials requires a focus on issues ranging from their potential questions and concerns about the studies to how and when doctors discuss clinical trials with their patients. One known problem is that many African-Americans have historical reasons to distrust the clinical trials system?a legacy of the infamous government-sponsored Tuskegee study in which several hundred poor African-American sharecroppers in Alabama were intentionally not treated for syphilis because researchers wanted to study how the disease naturally progresses."


"Nikita Robinson, a senior research coordinator at the M. D. Anderson Cancer Center in Houston, Texas, says that even though Tuskegee happened decades ago, it still comes up in her conversations with African-American patients, especially older ones, when she tries to recruit them for clinical trials. ?I tell them that ? those things don?t happen anymore,? she says. ?Research is controlled now. It?s governed by review boards. [Researchers] can?t just do whatever they want.?

"Lower participation isn?t only a result of patients choosing not to join or being ineligible. Studies have found that physicians do not discuss clinical trials with their African-American patients as often as they do with their white patients. ?Physicians might feel that some [African-American] patients will not be able to understand the consent process or have the ability to adhere to the protocol,? says Susan Eggly, a communications scientist at the Karmanos Cancer Institute at Wayne State University in Detroit who studies patient-physician communication. ?They also might presume that patients will be unwilling to participate.?








Click Here
 
Older cancer survivors in rural areas are more likely than those in urban areas to forgo medical and dental care because they can't afford it, a new study finds. Researchers analyzed data from more than 7,800 cancer survivors -- 1,642 from rural areas and 6,162 from urban areas -- who took part in the U.S. National Health Interview Surveys between 2006 and 2010. (More...)

Blacks with colon cancer are about half as likely as whites to get a type of colon cancer that has a better chance of survival, a new study says. (More...)

Obese women might be able to eliminate their increased risk for postmenopausal breast cancer by taking measures during perimenopause to prevent weight gain and to therapeutically control the metabolic effects of their obesity, according to the results of a preclinical study in an animal model from the University of Colorado Anschutz Health and Wellness Center, published in Cancer Research, a journal of the American Association for Cancer Research. The University of Colorado is home to the University of Colorado Cancer Center. (More...)

Human immunodeficiency virus (HIV) infection contributes substantially to the epidemic of anal cancer in men, but not women in the United States, according to new research from NCI. Anal cancer is rare, with an estimated 6,230 cases in 2012 but incidence rates in the U.S. have risen steadily over the past several decades. This new study documents that among men, half of this increase is explained by cases occurring in those who are HIV-positive. (More...)

Changing the Face of Clinical Trials: "Overall, only about 5 to 10 percent of cancer patients participate in clinical trials. And when it comes to African-American cancer patients, the figures are even lower: 2 to 4 percent. This low participation makes it difficult for researchers to get answers to critical questions: Why are African-Americans more likely to develop certain cancers than other racial and ethnic groups and have higher death rates for some types of the disease? Is it lifestyle? Genetics? Treatment response? Access to health care? No one yet knows. But researchers believe that increasing the number of African-Americans in cancer trials will help them find out. So that can happen, more efforts are under way to identify the reasons that so few African-American cancer patients join clinical trials?and to implement programs that can put them on the clinical trials track." (More...)

Vanderbilt study finds diverse genetic alterations in triple-negative breast cancers: Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators. Finding multiple mutations instead of just one primary mutation that can be targeted for therapy sheds more light on the challenges of treating triple-negative breast cancer. (More...)